Cuban Academy of Sciences develops vaccines for the treatment of non-small cell lung cancer- Vaxira and CIMAvax. This latest type of vaccine that can treat non-small cell lung cancer (NSCLC) has undergone phase 3 clinical validation and has a good effect on non-small cell lung cancer. It has now entered clinical applications in Cuba da kuma Peru. Sakamakon wannan binciken mai kayatarwa ya bawa tsohon Shugaban Amurka dama Barack Obama don ɗaga haramcin kasuwanci na shekaru 55 bayan ziyarta Cuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Menene CIMAvax?
CIMAvax-EGF is a kwayar cutar huhu treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced cututtukan daji na kansa marasa kansar (NSCLC).
Ta yaya CIMAvax ke aiki?
Developed by researchers at the Center for Molecular Immunology (CIM) in Havana, Cuba, CIMAvax-EGF blocks a type of protein — epidermal growth factor (EGF) — that cancer cells need to grow. It does not kill cells directly, cancerous cells or otherwise, but “starves” them by preventing EGF from attaching to its proper receptor (EGFR) on the cell. This connection is required for the cell to grow and proliferate. Without it, the cancer cell does not multiply, and dies. CIMAvax blocks EGF by manipulating the patient’s immune response.
Wani “furotin mai ɗauke” a cikin CIMAvax yana haifar da tsarin garkuwar jiki don samar da ƙwayoyin cuta akan furotin EGF don kawar da shi. Wannan yana rage yaduwar EGF daga jini, yana hana ƙwayoyin kansar wannan maɓallin mahimmanci don ci gaba da rayuwa.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged tumo stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Menene Vaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab shine anti-idiotypic monoclonal antibody wanda ke haifar da haƙuri ga marasa lafiya mai karfin gwiwa game da takamaiman glycolylated gangliosides (NeuGcGM3) da ke cikin ƙwayoyin tumo. Vaxira® yana haɓaka rayuwar marasa lafiya na NSCLC a cikin matakai na ci gaba ko na gaba (IIIB / IV) idan aka kwatanta da mafi kyawun kulawa na tallafi. Vaxira® yana da kyakyawan haƙuri kuma ana karɓar bayanan lafiyarsa. Yawancin abubuwan da suka faru na yau da kullun suna cikin gida (a wurin gudanarwa), mai sauƙi da jinkiri.
Ko da marasa lafiyar da aka yiwa rigakafin Vaxira® bayan cutar ta ci gaba sun nuna ci gaba a cikin rayuwa gabaɗaya.
Halitta: Kowane vial na VAXIRA® ya ƙunshi: mAb Racotumomab 1.00 mg, aluminum hydroxide [Al (OH) 3] 5.00 mg, tris (hydroxymethyl) aminomethane 12.14 mg, sodium chloride 3.40 mg, ruwa don allura qs 1.0 ml. Vaxira® wakili ne na rigakafi wanda ya hada da anti-idiotypic monoclonal antibody Racotumomab da aluminum hydroxide (AH), adjuvant mai amfani da yawa. AH yana haɓaka samar da ƙwayoyin cuta, amma ba rigakafi bane ko haɗuwa. Yana yin aiki a matsayin ma'aji a wurin da aka yi allurar daga inda aka sake antigen a hankali kuma, a lokaci guda, yana haifar da samuwar granulomas wanda ke jawo ƙwayoyin ƙwayoyin cuta kamar ƙwayoyin plasma masu samar da antibody. AH na iya yin tasiri kai tsaye ta hanyar amfani da sinadarai wadanda zasu iya kunna kwayar T, kuma hakan na iya haifar da da kwayar B.
Yadda zaka sayi CIMAvax da Vaxira a Indiya?
CIMAvax and Vaxira at present are not available in India. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
